DC Funds’s Werewolf Therapeutics HOWL Stock Holding History

DC Funds’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$490K	Hold	589,102	–	–	33.01%	2
2025 Q4	$373K	Hold	589,102	–	–	25.69%	3
2025 Q3	$1.16M	Hold	589,102	–	–	37.32%	1
2025 Q2	$642K	Hold	589,102	–	–	29.83%	2
2025 Q1	$573K	Hold	589,102	–	–	27.71%	3
2024 Q4	$872K	Hold	589,102	–	–	24.47%	2
2024 Q3	$1.25M	Hold	589,102	–	–	24.25%	2
2024 Q2	$1.44M	Hold	589,102	–	–	23.87%	2
2024 Q1	$3.82M	Hold	589,102	–	–	36.89%	2
2023 Q4	$2.27M	Hold	589,102	–	–	27.34%	3
2023 Q3	$1.26M	Hold	589,102	–	–	25.95%	3
2023 Q2	$1.8M	Hold	589,102	–	–	38.27%	1
2023 Q1	$1.53M	Hold	589,102	–	–	35.68%	1
2022 Q4	$1.21M	Hold	589,102	–	–	32.7%	2
2022 Q3	$2.66M	Hold	589,102	–	–	40.05%	1
2022 Q2	$2.41M	Hold	589,102	–	–	33.24%	2
2022 Q1	$2.59M	Buy	589,102 +8,200	+1%	+$57.4K	33.68%	2
2021 Q4	$6.92M	Sell	580,902 -8,200	-1%	-$124K	40.97%	2
2021 Q3	$10.1M	Hold	589,102	–	–	39.69%	1
2021 Q2	$10.3M	Buy	+589,102	New	+$8.07M	48.81%	2

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

DC Funds's HOWL Position: Q1 2026 in Review

DC Funds held its Werewolf Therapeutics (HOWL) position steady in Q1 2026 at 589,102 shares worth $490K. The position accounts for 33.01% of the portfolio, ranked #2.

DC Funds first reported a position in HOWL in Q2 2021 and has held it in 20 quarters since. The position peaked at $10.3M in Q2 2021. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

DC Funds held 589,102 shares of Werewolf Therapeutics worth $490K as of Q1 2026.
DC Funds left its Werewolf Therapeutics share count unchanged in Q1 2026.
Werewolf Therapeutics made up 33.01% of DC Funds's portfolio in Q1 2026, its #2 holding.
DC Funds first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 20 quarters since.
DC Funds's Werewolf Therapeutics position peaked at $10.3M in Q2 2021.
48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on DC Funds's 13F filing for Q1 2026, filed 14 May 2026.